Bronconex Acticap

Nazione: Nuova Zelanda

Lingua: inglese

Fonte: Medsafe (Medicines Safety Authority)

Principio attivo:

Mometasone furoate 400ug (anhydrous)

Commercializzato da:

Organon (New Zealand) Limited

INN (Nome Internazionale):

Mometasone furoate 400 µg (anhydrous)

Dosaggio:

400 mcg/dose

Forma farmaceutica:

Powder for inhalation

Composizione:

Active: Mometasone furoate 400ug (anhydrous) Excipient: Lactose

Confezione:

Inhaler, metered, DPI, (sample), 14 dose units

Classe:

Prescription

Tipo di ricetta:

Prescription

Prodotto da:

MSD International GmbH (Singapore Branch)

Indicazioni terapeutiche:

Bronconex Acticap is indicated for prophylactic therapy in the management of patients with asthma of all severities, including patients who have been dependent upon either inhaled or systemically administered corticosteroids and non-corticosteroid-dependent patients inadequately controlled on other drug regimens.

Dettagli prodotto:

Package - Contents - Shelf Life: Inhaler, metered, DPI, (sample) - 14 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 30 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 60 dose units - 18 months from date of manufacture stored at or below 25°C

Data dell'autorizzazione:

2000-12-05